MA52942A - Composés inhibiteurs d'oga - Google Patents
Composés inhibiteurs d'ogaInfo
- Publication number
- MA52942A MA52942A MA052942A MA52942A MA52942A MA 52942 A MA52942 A MA 52942A MA 052942 A MA052942 A MA 052942A MA 52942 A MA52942 A MA 52942A MA 52942 A MA52942 A MA 52942A
- Authority
- MA
- Morocco
- Prior art keywords
- inhibitor compounds
- oga inhibitor
- oga
- compounds
- inhibitor
- Prior art date
Links
- 229940126137 O-GlcNAcase inhibitor Drugs 0.000 title 1
- 150000001875 compounds Chemical class 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Neurosurgery (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Public Health (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Psychology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP18382456 | 2018-06-21 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA52942A true MA52942A (fr) | 2021-04-28 |
Family
ID=62784079
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA052942A MA52942A (fr) | 2018-06-21 | 2019-06-20 | Composés inhibiteurs d'oga |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20210277003A1 (fr) |
| EP (1) | EP3810586A1 (fr) |
| JP (1) | JP2021528404A (fr) |
| CN (1) | CN112313212B (fr) |
| AU (1) | AU2019291101A1 (fr) |
| CA (1) | CA3103049A1 (fr) |
| MA (1) | MA52942A (fr) |
| WO (1) | WO2019243535A1 (fr) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ754994A (en) | 2016-12-22 | 2022-12-23 | Amgen Inc | Benzisothiazole, isothiazolo[3,4-b]pyridine, quinazoline, phthalazine, pyrido[2,3-d]pyridazine and pyrido[2,3-d]pyrimidine derivatives as kras g12c inhibitors for treating lung, pancreatic or colorectal cancer |
| JOP20190272A1 (ar) | 2017-05-22 | 2019-11-21 | Amgen Inc | مثبطات kras g12c وطرق لاستخدامها |
| ES2928576T3 (es) | 2017-09-08 | 2022-11-21 | Amgen Inc | Inhibidores de KRAS G12C y métodos de uso de los mismos |
| MA52501A (fr) | 2018-05-04 | 2021-03-10 | Amgen Inc | Inhibiteurs de kras g12c et leurs procédés d'utilisation |
| CA3099118A1 (fr) | 2018-05-04 | 2019-11-07 | Amgen Inc. | Inhibiteurs de kras g12c et leurs procedes d'utilisation |
| EP3802535B1 (fr) | 2018-06-01 | 2022-12-14 | Amgen, Inc | Inhibiteurs de kras g12c et leurs procédés d'utilisation |
| MA51848A (fr) | 2018-06-12 | 2021-04-21 | Amgen Inc | Inhibiteurs de kras g12c et leurs procédés d'utilisation |
| JP7516029B2 (ja) | 2018-11-16 | 2024-07-16 | アムジエン・インコーポレーテツド | Ｋｒａｓ ｇ１２ｃ阻害剤化合物の重要な中間体の改良合成法 |
| JP7377679B2 (ja) | 2018-11-19 | 2023-11-10 | アムジエン・インコーポレーテツド | がん治療のためのｋｒａｓｇ１２ｃ阻害剤及び１種以上の薬学的に活性な追加の薬剤を含む併用療法 |
| US11053226B2 (en) | 2018-11-19 | 2021-07-06 | Amgen Inc. | KRAS G12C inhibitors and methods of using the same |
| EP3738593A1 (fr) | 2019-05-14 | 2020-11-18 | Amgen, Inc | Dosage d'inhibiteur de kras pour le traitement de cancers |
| EP3972973A1 (fr) | 2019-05-21 | 2022-03-30 | Amgen Inc. | Formes à l'état solide |
| WO2021097207A1 (fr) * | 2019-11-14 | 2021-05-20 | Amgen Inc. | Synthèse améliorée de composés inhibiteurs de kras g12c |
| IL314883A (en) | 2022-03-07 | 2024-10-01 | Amgen Inc | A process for preparing 4-methyl-2-propan-2-yl-pyridine-3-carbonitrile |
| CN114573467B (zh) * | 2022-03-21 | 2023-11-21 | 北京印刷学院 | 2，4-二甲基-3-氨基苯甲酸的合成工艺 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107108601B (zh) * | 2014-08-28 | 2021-08-20 | 阿森纽荣股份公司 | 糖苷酶抑制剂 |
| US10913733B2 (en) * | 2015-12-18 | 2021-02-09 | Alectos Therapeutics Inc. | Substituted piperidines thiazolyl acetamides as glycosidase inhibitors and uses thereof |
| WO2017144633A1 (fr) * | 2016-02-25 | 2017-08-31 | Asceneuron S. A. | Inhibiteurs de glycosidases |
| SG11201807012QA (en) * | 2016-02-25 | 2018-09-27 | Asceneuron S A | Acid addition salts of piperazine derivatives |
-
2019
- 2019-06-20 CA CA3103049A patent/CA3103049A1/fr active Pending
- 2019-06-20 EP EP19733712.4A patent/EP3810586A1/fr not_active Withdrawn
- 2019-06-20 AU AU2019291101A patent/AU2019291101A1/en not_active Abandoned
- 2019-06-20 CN CN201980041118.XA patent/CN112313212B/zh not_active Expired - Fee Related
- 2019-06-20 MA MA052942A patent/MA52942A/fr unknown
- 2019-06-20 WO PCT/EP2019/066394 patent/WO2019243535A1/fr not_active Ceased
- 2019-06-20 JP JP2020570424A patent/JP2021528404A/ja not_active Withdrawn
- 2019-06-20 US US17/253,505 patent/US20210277003A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| US20210277003A1 (en) | 2021-09-09 |
| AU2019291101A1 (en) | 2021-01-07 |
| EP3810586A1 (fr) | 2021-04-28 |
| CN112313212B (zh) | 2023-05-05 |
| CN112313212A (zh) | 2021-02-02 |
| JP2021528404A (ja) | 2021-10-21 |
| WO2019243535A1 (fr) | 2019-12-26 |
| CA3103049A1 (fr) | 2019-12-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA52939A (fr) | Composés inhibiteurs d'oga | |
| MA52942A (fr) | Composés inhibiteurs d'oga | |
| MA47420A (fr) | Composés inhibiteurs d'oga | |
| IL292753A (en) | Compounds | |
| MA47575A (fr) | Composés inhibiteurs d'oga monocyclique | |
| EP3836923A4 (fr) | Composés pyrrolo-dipyridine | |
| MA47576A (fr) | Composés inhibiteurs d'oga bicyclique | |
| EP3941898C0 (fr) | Composés fongicides | |
| MA52948A (fr) | Composés | |
| EP3737672A4 (fr) | Composés benzamide | |
| IL286833A (en) | Compositions containing brazzein | |
| MA51669A (fr) | Composés | |
| EP3906029A4 (fr) | Inhibiteurs de l'interaction ménine-mll | |
| DK4083038T3 (da) | Pyridazinylthiazolcarboxamidforbindelse | |
| EP3464275A4 (fr) | Composés inhibiteurs de l'egfr | |
| MA53003A (fr) | Composés | |
| MA52004A (fr) | Inhibiteurs d'o-glycoprotéine-2-acétamido-2-désoxy-3-d-glycopyranosidase | |
| MA49006A (fr) | Inhibiteurs d'ip6k | |
| MA54521A (fr) | Dérivés d'oxopyridine substitués | |
| EP4077318A4 (fr) | Composés | |
| MA52946A (fr) | Composés | |
| EP3833342A4 (fr) | Composés d'imidazotétrazine | |
| EP3808747A4 (fr) | Composé d'imidazopyridinone | |
| MA53648A (fr) | Inhibiteurs d'o-glycoprotéine-2-acétamido-2-désoxy-3-d-glucopyranosidase | |
| EP4003986A4 (fr) | Composés inhibiteurs |